# Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy

> **NCT00005634** · PHASE1 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center**

## Conditions studied

- Leukemia
- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Prostate Cancer
- Small Intestine Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** vorinostat

## Key facts

- **NCT ID:** NCT00005634
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-01
- **Primary completion:** 2002-10
- **Final completion:** 2002-10
- **Target enrollment:** — (—)
- **Last updated:** 2013-06-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00005634

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00005634, "Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00005634. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*